Cargando…
Protective effect of Secukinumab on severe sepsis model rats by neutralizing IL-17A to inhibit IKBα/NFκB inflammatory signal pathway
Secukinumab is a specific neutralizing antibody for IL-17A. At present, numerous studies have confirmed the important role of IL-17A in sepsis, but the role of secukinumab in sepsis has not been studied. The present study explored the protective effect and underlying mechanism of secukinumab in seve...
Autores principales: | Wang, Xingsheng, Zhang, Xinxin, Sun, Li, Gao, Guangsheng, Li, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578221/ https://www.ncbi.nlm.nih.gov/pubmed/36253831 http://dx.doi.org/10.1186/s40001-022-00845-2 |
Ejemplares similares
-
Tofacitinib reduces acute lung injury and improves survival in a rat model of sepsis by inhibiting the JAK-STAT/NF-κB pathway
por: Zhang, Xinxin, et al.
Publicado: (2023) -
Interfering microRNA-410 attenuates atherosclerosis via the HDAC1/KLF5/IKBα/NF-κB axis
por: Nan, Shanji, et al.
Publicado: (2021) -
Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab
por: Grosskreutz, Cynthia L., et al.
Publicado: (2015) -
Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019) -
Changes of KEAP1/NRF2 and IKB/NF-κB Expression Levels Induced by Cell-Free DNA in Different Cell Types
por: Kostyuk, Svetlana V., et al.
Publicado: (2018)